1. Scrip
  2. >>Business

AstraZeneca Under Soriot: Progress Report

 
• By Eleanor Malone

Last week, AstraZeneca's CEO Pascal Soriot was rumored to be preparing for a move to run Teva Pharmaceutical Industries. This week, he's rumored to be staying put. Scrip takes a look at the key moments in his tenure at the UK big pharma, and the progress on targets.

Report card
How is Soriot doing in Year 5 at AstraZeneca?

Rumors swirl around AstraZeneca PLC's CEO of five years, Pascal Soriot. The company's market capitalization slipped by £2.45bn (-3.7%) on Thursday and Friday last week amid claims he was preparing to join Teva Pharmaceutical Industries Ltd., which has been hunting for a CEO since February. Over the weekend, AstraZeneca said Soriot would be presenting the company's quarterly results on 27 July and speculation switched to the likelihood that Soriot will stay at AZ, sending Teva's shares into a 3.1% decline. Scrip takes a look at the track record of the man who can cause so much market turbulence.

Brought in to run the UK big pharma in 2012 after his predecessor David Brennan was squeezed into retirement, Soriot launched a restructuring program to simplify the company's business, consolidate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.